Microglial activity—indicative of an immune response to neuroinflammation—appears to be elevated in ...
People with schizophrenia may be at a higher risk for dementia with an earlier age at onset than tho...
The Food and Drug Administration (FDA) last week approved Vraylar (cariprazine), a dopamine D2/D3 re...
Yesterday, the Food and Drug Administration announced that it is making changes to the requirements ...
Although it is well established that patients with schizophrenia have deficits in cortical gray matt...
The ability to firmly diagnose schizophrenia before symptoms of the disease arise can help improve p...
Patients with a recent first episode of schizophrenia who are treated with a long-acting injectable ...
New findings from a phase 3 clinical trial, published today in AJP in Advance, suggest that a recent...
A three-month formulation of paliperidone palmitate administered four times yearly as a long-acting ...
